Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Brian Quigley_2024
VIEWPOINTS

Tackling Pulmonary Infections: Brian Quigley Sheds Light on Qnovia’s Recent Partnership with the University of Virginia

Shots:  Following Qnovia’s recent partnership with the University of Virginia, Brian Quigley engages in a stimulating conversation with PharmaShots   The collaboration adds two assets, QN-05 for the treatment of pneumonia and QN-06 for the treatment of pulmonary infection caused by B. anthracis, to Qnovia’s portfolio   During a discussion of Qnovia's proprietary drug delivery platform RespiRx,…
January 8, 2024

Read more

Viewpoints_Brian Quigley
VIEWPOINTS

Brian Quigley, CEO at Qnovia Shares Insights on Respira Technologies Rebranded as Qnovia

Shots: Brian spoke about why Respira Technologies has been rebranded as Qnovia Brian also talked about how Qnovia is working to advance its first inhalable prescription smoking cessation therapy and its applications The interview summarizes how this rebranding will accelerate Qnovia’s technology and products from others in the biotechnology space  Smriti: Would you please start off…
December 12, 2022

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]